Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia

International Journal of Antimicrobial Agents

Volumn 51, Issue 1, 2018, Pages 47-51

  Huang, Ying Chi ^a   Lin, Yi Tsung ^a,b   Wang, Fu Der ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bacteraemia; Fluoroquinolone; Treatment

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; QUINOLONE DERIVATIVE;

AGED; APACHE; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELIZABETHKINGIA MENINGOSEPTICA; FEMALE; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY RATE; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENT INFECTION; RETROSPECTIVE STUDY; TAIWAN; ANALOGS AND DERIVATIVES; CHRYSEOBACTERIUM; CLASSIFICATION; COMPARATIVE STUDY; CROSS INFECTION; DRUG EFFECT; FLAVOBACTERIACEAE INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORTALITY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHRYSEOBACTERIUM; CROSS INFECTION; FEMALE; FLAVOBACTERIACEAE INFECTIONS; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; TAIWAN; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 85035346244     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.05.018     Document Type: Article

References (27)

1. Kim, K.K., Kim, M.K., Lim, J.H., Park, H.Y., Lee, S.T., Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov. Int J Syst Evol Microbiol 55 (2005), 1287–1293.
2. Chiu, C.H., Waddingdon, M., Greenberg, D., Schreckenberger, P.C., Carnahan, A.M., Atypical Chryseobacterium meningosepticum and meningitis and sepsis in newborns and the immunocompromised, Taiwan. Emerg Infect Dis 6 (2000), 481–486.
3. Bloch, K.C., Nadarajah, R., Jacobs, R., Cryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore) 76 (1997), 30–41.
4. Moore, L.S., Owens, D.S., Jepson, A., Turton, J.F., Ashworth, S., Donaldson, H., et al. Waterborne Elizabethkingia meningoseptica in adult critical care. Emerg Infect Dis 22 (2016), 9–17.
5. Balm, M.N., Salmon, S., Jureen, R., Teo, C., Mahdi, R., Seetoh, T., et al. Bad design, bad practices, bad bugs: frustrations in controlling an outbreak of Elizabethkingia meningoseptica in intensive care units. J Hosp Infect 85 (2013), 134–140.
6. Lin, Y.T., Chiu, C.H., Chan, Y.J., Lin, M.L., Yu, K.W., Wang, F.D., et al. Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan. Scand J Infect Dis 41 (2009), 628–634.
7. Hsu, M.S., Liao, C.H., Huang, Y.T., Liu, C.Y., Yang, C.J., Kao, K.L., et al. Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999–2006. Eur J Clin Microbiol Infect Dis 30 (2011), 1271–1278.
8. Jean, S.S., Lee, W.S., Chen, F.L., Ou, T.Y., Hsueh, P.R., Elizabethkingia meningoseptica: an important emerging pathogen causing healthcare-associated infections. J Hosp Infect 86 (2014), 244–249.
9. Hung, P.P., Lin, Y.H., Lin, C.F., Liu, M.F., Shi, Z.Y., Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality. J Microbiol Immunol Infect 41 (2008), 137–144.
10. Lin, P.Y., Chen, H.L., Huang, C.T., Su, L.H., Chiu, C.H., Biofilm production, use of intravascular indwelling catheters and inappropriate antimicrobial therapy as predictors of fatality in Chryseobacterium meningosepticum bacteraemia. Int J Antimicrob Agents 36 (2010), 436–440.
11. Kirby, J.T., Sader, H.S., Walsh, T.R., Jones, R.N., Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: report from the SENTRY Antimicrobial Surveillance Program (1997–2001). J Clin Microbiol 42 (2004), 445–448.
12. Sader, H.S., Jones, R.N., Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 25 (2005), 95–109.
13. Wang, Y.L., Scipione, M.R., Dubrovskaya, Y., Papadopoulos, J., Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 58 (2014), 176–182.
14. Cho, S.Y., Kang, C.I., Kim, J., Ha, Y.E., Chung, D.R., Lee, N.Y., et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?. Antimicrob Agents Chemother 58 (2014), 581–583.
15. Hagiya, H., Ogawa, H., Takahashi, Y., Hasegawa, K., Iwamuro, M., Otsuka, F., A nephrostomy-associated urinary tract infection caused by Elizabethkingia meningoseptica. Intern Med 54 (2015), 3233–3236.
16. Lee, S.W., Tsai, C.A., Lee, B.J., Chryseobacterium meningosepticum sepsis complicated with retroperitoneal hematoma and pleural effusion in a diabetic patient. J Chin Med Assoc 71 (2008), 473–476.
17. Lee, C.H., Lin, W.C., Chia, J.H., Su, L.H., Chien, C.C., Mao, A.H., et al. Community-acquired osteomyelitis caused by Chryseobacterium meningosepticum: case report and literature review. Diagn Microbiol Infect Dis 60 (2008), 89–93.
18. Friedman, N.D., Kaye, K.S., Stout, J.E., McGarry, S.A., Trivette, S.L., Briggs, J.P., et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137 (2002), 791–797.
19. Wu, H.S., Wang, F.D., Tseng, C.P., Wu, T.H., Lin, Y.T., Fung, C.P., Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect 64 (2012), 162–168.
20. Durante-Mangoni, E., Casillo, R., Bernardo, M., Caianiello, C., Mattucci, I., Pinto, D., et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54 (2012), 347–354.
21. Wayne, P., Clinical and Laboratory Standards Institute: performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. 2012, CLSI.
22. Vincent, J.L., Bassetti, M., Francois, B., Karam, G., Chastre, J., Torres, A., et al. Advances in antibiotic therapy in the critically ill. Crit Care, 20, 2016, 133.
23. Blot, S.I., Pea, F., Lipman, J., The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77 (2014), 3–11.
24. Neuner, E.A., Ahrens, C.L., Groszek, J.J., Isada, C., Vogelbaum, M.A., Fissell, W.H., et al. Use of therapeutic drug monitoring to treat Elizabethkingia meningoseptica meningitis and bacteraemia in an adult. J Antimicrob Chemother 67 (2012), 1558–1560.
25. Levitz, R.E., Quintiliani, R., Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 100 (1984), 881–890.
26. Samonis, G., Karageorgopoulos, D.E., Maraki, S., Levis, P., Dimopoulou, D., Spernovasilis, N.A., et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS ONE, 7, 2012, e37375.
27. Hand, E., Davis, H., Kim, T., Duhon, B., Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother 71 (2016), 1071–1075.